# Ixabepilone to Treat Cervical Cancer

> **NCT00924066** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 41 (actual)

## Conditions studied

- Cervical Carcinoma
- Cervical Adenocarcinoma
- Cervical Adenosquamous Carcinoma
- Cervical Carcinoma, Non-SquamousType

## Interventions

- **DRUG:** Ixempra (Ixabepilone (BMS-247550) )

## Key facts

- **NCT ID:** NCT00924066
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-11
- **Primary completion:** 2013-12
- **Final completion:** 2013-12
- **Target enrollment:** 41 (ACTUAL)
- **Why stopped:** Premature closure due to slow/insufficient accrual.
- **Last updated:** 2019-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00924066

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00924066, "Ixabepilone to Treat Cervical Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00924066. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*